Market Cap 70.40M
Revenue (ttm) 128.94M
Net Income (ttm) -85.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -66.23%
Debt to Equity Ratio 0.00
Volume 90,400
Avg Vol 63,094
Day's Range N/A - N/A
Shares Out 5.96M
Stochastic %K 67%
Beta 0.18
Analysts Sell
Price Target $14.00

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Ket...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 623 4211
Address:
1280 Rancho Conejo Blvd, Thousand Oaks, United States
Smurfologist
Smurfologist Jul. 30 at 4:56 PM
$ATRA is showin' out for them doubters out there; YOU BETTA RECOGNIZE!!! 🙏🏾🐃💪🏾💣💥🚀
0 · Reply
VENIVICI
VENIVICI Jul. 25 at 6:49 PM
Holding $ATRA tight into quarterly earnings. 🍿🍿🍿
3 · Reply
Smurfologist
Smurfologist Jul. 25 at 2:27 PM
$ATRA Stocks rise; stocks fall.....THAT'S WHUT STOCKS DO. When stocks do whut they do, what matters is whut YOU do!! Gonna stack my chips so that when this stock bounce up, my pockets will git phat!!! There will always be haters out there. You have to do YOU!! Good luck to those that will stick around for the prize!! 🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Newe0815
Newe0815 Jul. 24 at 9:44 PM
$ATRA The run will now probably be over, the hope was probably on a Class 1 classification. Now there will be nothing to report until January.
1 · Reply
takingstock73
takingstock73 Jul. 24 at 5:05 PM
$ATRA class 1 would have been better , but I think it still academic from here , just won't have 100% til Jan
0 · Reply
Lazyhitman817
Lazyhitman817 Jul. 24 at 4:32 PM
$ATRA what was the sell off after pre market… was the approval of resubmission good ?
0 · Reply
prismmarketview
prismmarketview Jul. 24 at 1:26 PM
Nasdaq: $ATRA @Atarabio’ tab-cel has received FDA Priority Review for EBV+ PTLD, a rare post-transplant cancer. A decision is expected by Jan 15, 2025—potentially making it the first approved therapy for this life-threatening disease. https://prismmarketview.com/atara-biotherapeutics-tab-cel-receives-fda-priority-review-for-ebv-post-transplant-lymphoproliferative-disease/
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 1:09 PM
$ATRA PT 14
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 1:09 PM
$ATRA https://www.businesswire.com/news/home/20250724273588/en/Atara-Biotherapeutics-Announces-U.S.-FDA-Acceptance-and-Priority-Review-of-the-Biologics-License-Application-for-Tabelecleucel-Tab-cel-for-the-Treatment-of-Epstein-Barr-Virus-Positive-Post-Transplant-Lymphoproliferative-Disease
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 1:03 PM
$ATRA Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) By PR Newswire | July 24, 2025, 8:57 AM
0 · Reply
Latest News on ATRA
Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 15, 2025, 8:30 AM EDT - 2 months ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering


US FDA declines to approve Atara Biotherapeutics' cancer therapy

Jan 16, 2025, 8:41 AM EST - 6 months ago

US FDA declines to approve Atara Biotherapeutics' cancer therapy


Smurfologist
Smurfologist Jul. 30 at 4:56 PM
$ATRA is showin' out for them doubters out there; YOU BETTA RECOGNIZE!!! 🙏🏾🐃💪🏾💣💥🚀
0 · Reply
VENIVICI
VENIVICI Jul. 25 at 6:49 PM
Holding $ATRA tight into quarterly earnings. 🍿🍿🍿
3 · Reply
Smurfologist
Smurfologist Jul. 25 at 2:27 PM
$ATRA Stocks rise; stocks fall.....THAT'S WHUT STOCKS DO. When stocks do whut they do, what matters is whut YOU do!! Gonna stack my chips so that when this stock bounce up, my pockets will git phat!!! There will always be haters out there. You have to do YOU!! Good luck to those that will stick around for the prize!! 🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Newe0815
Newe0815 Jul. 24 at 9:44 PM
$ATRA The run will now probably be over, the hope was probably on a Class 1 classification. Now there will be nothing to report until January.
1 · Reply
takingstock73
takingstock73 Jul. 24 at 5:05 PM
$ATRA class 1 would have been better , but I think it still academic from here , just won't have 100% til Jan
0 · Reply
Lazyhitman817
Lazyhitman817 Jul. 24 at 4:32 PM
$ATRA what was the sell off after pre market… was the approval of resubmission good ?
0 · Reply
prismmarketview
prismmarketview Jul. 24 at 1:26 PM
Nasdaq: $ATRA @Atarabio’ tab-cel has received FDA Priority Review for EBV+ PTLD, a rare post-transplant cancer. A decision is expected by Jan 15, 2025—potentially making it the first approved therapy for this life-threatening disease. https://prismmarketview.com/atara-biotherapeutics-tab-cel-receives-fda-priority-review-for-ebv-post-transplant-lymphoproliferative-disease/
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 1:09 PM
$ATRA PT 14
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 1:09 PM
$ATRA https://www.businesswire.com/news/home/20250724273588/en/Atara-Biotherapeutics-Announces-U.S.-FDA-Acceptance-and-Priority-Review-of-the-Biologics-License-Application-for-Tabelecleucel-Tab-cel-for-the-Treatment-of-Epstein-Barr-Virus-Positive-Post-Transplant-Lymphoproliferative-Disease
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 1:03 PM
$ATRA Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) By PR Newswire | July 24, 2025, 8:57 AM
0 · Reply
ballyhooo
ballyhooo Jul. 24 at 12:38 PM
$ATRA The BLA has been granted Priority Review with a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026.
0 · Reply
ballyhooo
ballyhooo Jul. 24 at 12:01 PM
$ATRA Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
0 · Reply
Smurfologist
Smurfologist Jul. 23 at 5:55 PM
$ATRA Profit-taking?!? 🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Smurfologist
Smurfologist Jul. 23 at 2:20 PM
$ATRA $13.50?!? I think she got it in her......LET'S GO, GURL!!!🙏🏾🐃💪🏾💣💥🚀
0 · Reply
moncor
moncor Jul. 22 at 11:47 PM
$ABVX watch out guys...next will be $ATRA!!!!
1 · Reply
moncor
moncor Jul. 22 at 11:45 PM
$ABVX for those of you who missed this monster move like me, check out $ATRA. This will be running fast to the fifty's or hundreds soon...Congrats to all those who have $ABVX. Soon it will be $ATRA!!!!
0 · Reply
BullRun4
BullRun4 Jul. 22 at 7:32 PM
$ATRA very bullish
0 · Reply
Smurfologist
Smurfologist Jul. 22 at 5:47 PM
$ATRA JUST WoW!!!🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Smurfologist
Smurfologist Jul. 22 at 2:00 PM
$ATRA is showing out rat now.....Are we good for $13.00 today?!? ALL ABOARD!!! 🙏🏾🐃💪🏾💣💥🚀
0 · Reply
takingstock73
takingstock73 Jul. 22 at 1:59 PM
$ATRA low volume run , any theories ?
0 · Reply
Lazyhitman817
Lazyhitman817 Jul. 22 at 1:48 PM
$ATRA has this on my watchlist for a week and got in yesterday based off my indicators as it’s apparent it will run for little, but anyone know the reason for this little breakout or what? Or is it solely technical
1 · Reply
hassle
hassle Jul. 22 at 8:06 AM
0 · Reply